CABA — Cabaletta Bio, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1759138 ·
Last close
$1.02
Market Cap
$220.03M
52W High
$4.23
52W Low
$0.98
ADV30
4,747,691
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -54,707,000 | -53,053,000 | 336,491,000 | 299,383,000 | 52,572,000 |
| Jun 2026 | 0 | — | -52,021,000 | -51,018,000 | 256,728,000 | 225,101,000 | 46,135,000 |
| Mar 2026 | 0 | — | -44,296,000 | -43,515,000 | 148,146,000 | 116,635,000 | 44,841,000 |
| Dec 2025 | 0 | — | -42,611,000 | -41,919,000 | 165,083,000 | 82,982,000 | 53,032,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-162,162,000
Investing CF
$100,613,000
Financing CF
$300,772,000
CapEx
$-1,229,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.45
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-664,543,000
Inventory
—
Receivables
—
ST Investments
$0
EBIT TTM
$-187,286,000
Pretax Income TTM
$-189,505,000
Interest Exp TTM
$2,219,000
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -172,241,000 | -167,856,000 | 165,083,000 | 53,032,000 | 112,051,000 | -131,080,000 |
| Dec 2024 | 0 | -125,141,000 | -115,864,000 | 185,046,000 | 32,711,000 | 152,335,000 | -88,222,000 |
| Dec 2023 | 0 | -74,660,000 | -67,675,000 | 253,650,000 | 17,452,000 | 236,198,000 | -53,549,000 |
| Dec 2022 | 0 | -54,139,000 | -52,975,000 | 116,968,000 | 12,448,000 | 104,520,000 | -46,380,000 |
TTM Snapshot
Revenues TTM
$5,814,000
NetIncome TTM
$-181,318,000
OpCashFlow TTM
—
Assets (Latest)
$256,728,000
Forward EPS
$-1.19
Max Pain — expiry 2027-01-15
max pain strike: $1.50 · spot: $1.05 · call oi: 9,264 · put oi: 349
Expected Move to 2027-01-15:
±$0.40
(37.91%) —
implied range
$0.65 –
$1.46
· ATM straddle on $1.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PROK | PROKIDNEY CORP. | $229.87M | $1.10 | — |
| LXEO | Lexeo Therapeutics, Inc. | $234.24M | $2.86 | — |
| LCTX | Lineage Cell Therapeutics, Inc. | $206.36M | $0.82 | — |
| PLX | Protalix BioTherapeutics, Inc. | $242.84M | $2.88 | — |
| DTIL | PRECISION BIOSCIENCES INC | $196.95M | $7.05 | — |
News headlines (Yahoo Finance, 1h cache)
Cabaletta Bio Presents New Rese-cel Phase 1/2 Clinical Data at ACR Convergence 2026 Featuring Immunomodulator-Free Durability and Favorable Benefit-Risk Profile Across Autoimmune Diseases
2026-11-08 15:00 · Yahoo
Cabaletta Bio Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-05 12:30 · Yahoo
Cabaletta Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-04 21:01 · Yahoo
Cabaletta Bio to Participate in Upcoming Investor Conferences
2026-11-03 13:00 · Yahoo
Cabaletta Bio (CABA) Upgraded to Buy: Here's Why
2026-05-18 16:00 · Yahoo
Cabaletta Bio Inc. (CABA) A Top Penny Stock Eyeing Rese-Cel Commercial Launch for Autoimmune Diseases
2026-06-07 17:58 · Yahoo
Cabaletta Bio Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-14 11:05 · Yahoo
Is Cabaletta Bio (CABA) Stock Outpacing Its Medical Peers This Year?
2026-05-20 13:40 · Yahoo
Pemphigus Vulgaris Market Analysis Report 2026-2036, Profiles of F. Hoffmann La Roche, Argenx, Sanofi, Syntimmune, Allmiral, Cabaletta Bio, and Novartis
2026-05-21 11:42 · Yahoo
Cabaletta Bio Announces New Rese-cel Data and Development Updates Across Autoimmune Portfolio, Including Encouraging Early PC-Free Lupus Findings, at EULAR 2026 Congress
2026-06-03 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.